This will be a two day meeting  for clinical pharmacologists, scientists and pediatricians to discuss overcoming the scientific challenges using tools such as models & simulations and PK & PD studies to optimise the development of new pediatric medicines.

It is well known that recent regulatory changes in the USA and Europe have made it mandatory to further development of  medicines for children. Many previous discussions have taken place on the impact these regulatory changes have had or the difficult topics of locating willing pediatric populations and informed consent. 

However NextLevel Pharma’s focused and interactive event will look to 
concentrate on the importance and place of pharmacokinetic and 
pharmacodynamic studies to answer the questions of how children 
metabolize drugs differently. It will explore the best use of modeling and 
Simulations, what extrapolation is possible from existing data, how to assess optimal drug dosage levels, measure the drugs interactions on child physiology with minimal samples and subjects to optimise the design of studies for pediatric treatments. 

Experienced industry pharmacologists and pediatricians will join us to 
discuss recent developments and assess how to better understand optimum drug formulation and dosage, as well as measure the efficacy and understand the drugs interactions. 

Why Attend?

Hear fresh perspectives from experienced pharmaceutical companies 
who have designed successful  pk/pd pediatric studies.

Learn what place pk/pd studies have in the development of pediatric 
drugs and how they can be used more effectively to determine 
dosages, measure efficacy and demonstrate value to the pediatric world.

Hear case study presentations from industry leaders on how to adapt 
methods used from adult to children.

Discover what approaches are best to predict dosage, utilize existing 
adult) data, and understand the interactions between drug and child.

Who will benefit

Pharmaceutical & Biotechnology Organisations: 
Vice- Presidents, Directors, Managers;
Pediatrics, Pre-Clinical and Clinical Pharmacologists, Modeling and 
Simulation Specialists, 

CROs & Solution Providers:
CEOs, Business Development Directors, Product Managers,
Marketing Managers 

Academics;
Pediatricians, pharmacologists and scientists involved in the 
development of new pediatric medicines

About the Venue

If ever a city could claim split personality, it’s Brussels. French versus 
Flemish, historic versus hip, bizarre versus boring. Full of contrasts, 
contradictions and intrigue, this is a multicultural equation that goes much deeper than you would think. An historic heirloom is closer to the mark. And in an age where so much is already discovered, Belgium’s capital seduces as one of Western Europe’s unknowns. 
Brussels also benefits from being at the “cross-roads” of Europe and that is why it is a superb venue for this conference, strategically located in the northern European epicentre of commerce and business.

INDUSTRY EXPERTS

Associate Medical Director

Orphan Europe, France

Research Scientist

Novo Nordisk, Denmark

(TBC)

Senior Director Global

Exploratory Development

UCB Pharma, Belgium

Senior Clinical Pharmacologist, Clinical Pharmacology

DBA - Metabolic Diseases Roche, Switzerland

CSO & founding board Director

Promethera Biosciences & President

Pediatric Department

Université Catholique de Louvain, Belgium

ACADEMIA

Pediatric intensivist Pediatrician clinical pharmacologist

Erasmus MC Sophia

Children's Hospital Intensive Care, The Netherlands

University Hospitals Leuven, Belgium (TBC)

Professor of Systems

Pharmacology, School of Pharmacy and

Pharmaceutical Sciences

University of Manchester, UK